XBiotech (XBIT)
(Delayed Data from NSDQ)
$5.70 USD
-0.09 (-1.55%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $5.67 -0.03 (-0.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XBIT 5.70 -0.09(-1.55%)
Will XBIT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for XBIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XBIT
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
XBIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for XBIT
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech trading resumes
XBiotech announces data from Phase 1/2 1-BETTER study
XBiotech trading halted, volatility trading pause
XBiotech: Several Shots On Goal In Big Target Market Indications